Engraftment rate (primary outgrowth); percentage of biopsies which develop xenografts. Latency Percentage of biopsies resulting in stable lines Percentage of biopsies resulting in lymphomas. Clinical characteristics of patient tumour tissue Validation Comparison of xenograft and tumour histology 15. Specify the outcome measures Confirmation of human tumour cells exclusion of mouse cells and normal human cells for primary outgrowth only) Confirmation of tissue type Confirmation of cellular type Confirmation of tumour markers Confirmation of lymphoma or EBV (T cell, B cell, NK cell) State your research question (based How well validated are mouse xenografts derived from 16. on items 11-15) human carcinoma tissues C. Methods Search and study identification XMEDLINE □Web via PubMed of Science □SCOPUS XEMBASE Identify literature databases to search 17. (e.g. Pubmed, Embase, Web of □Other, namely: science) □Specific journal(s), namely: Define electronic search strategies When available, please add a supplementary file 18. (e.g. use the and animal search filters containing your search strategy: [insert file name] ) XReference □Books lists of included studies □Reference lists of relevant reviews Identify other sources for study □Conference 19. proceedings, namely: identification □Contacting authors/ organisations, namely: □Other, namely: Define search strategy for these other 20. NA sources Study selection Search results will be loaded onto the systematic review web app, Rayyan, to allow title and abstract screening. Titles and abstracts identified through electronic database and web searching will be independently screened by two Define screening phases (e.g. reviewers. Title and abstract screening will be based on 21. based on title/abstract, full population, language and publication type only. text screening, both) Articles meeting the inclusion criteria will be obtained as full paper copies and examined independently by two reviewers to determine whether the full paper meets the inclusion criteria of the review. All papers excluded at this
15. Specify the outcome measures Engraftment rate (primary outgrowth); percentage of biopsies which develop xenografts. Latency Percentage of biopsies resulting in stable lines Percentage of biopsies resulting in lymphomas. Clinical characteristics of patient tumour tissue Validation Comparison of xenograft and tumour histology Confirmation of human tumour cells exclusion of mouse cells and normal human cells for primary outgrowth only) Confirmation of tissue type Confirmation of cellular type Confirmation of tumour markers Confirmation of lymphoma or EBV (T cell, B cell, NK cell) 16. State your research question (based on items 11-15) How well validated are mouse xenografts derived from human carcinoma tissues C. Methods Search and study identification 17. Identify literature databases to search (e.g. Pubmed, Embase, Web of science) XMEDLINE via PubMed □Web of Science □SCOPUS XEMBASE □Other, namely: □Specific journal(s), namely: 18. Define electronic search strategies (e.g. use the and animal search filters ) When available, please add a supplementary file containing your search strategy: [insert file name] 19. Identify other sources for study identification XReference lists of included studies □Books □Reference lists of relevant reviews □Conference proceedings, namely: □Contacting authors/ organisations, namely: □Other, namely: 20. Define search strategy for these other sources NA Study selection 21. Define screening phases (e.g. based on title/abstract, full text screening, both) Search results will be loaded onto the systematic review web app, Rayyan, to allow title and abstract screening. Titles and abstracts identified through electronic database and web searching will be independently screened by two reviewers. Title and abstract screening will be based on population, language and publication type only. Articles meeting the inclusion criteria will be obtained as full paper copies and examined independently by two reviewers to determine whether the full paper meets the inclusion criteria of the review. All papers excluded at this